SCHEMBL393316

SCHEMBL393316

OC(Cc1ccc(OCc2ccccc2)cc1)c1cc(OCc2ccccc2)cc(OCc2ccccc2)c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.56
CYP1A2 P05177 1/20 0.56
PTGS1 P23219 1/20 0.56
SLC6A2 P23975 1/20 0.56
CYP2C19 P33261 1/20 0.56
PTGS2 P35354 1/20 0.56
SLC6A3 Q01959 1/20 0.56
HIF1A Q16665 1/20 0.56
HDAC6 Q9UBN7 1/20 0.56
LTA4H P09960 4/20 0.55
PPARG P37231 2/20 0.55
PPARA Q07869 2/20 0.55
LAP3 P28838 1/20 0.55
FFAR1 O14842 2/20 0.54
FFAR4 Q5NUL3 1/20 0.54
MEN1 O00255 1/20 0.53
KMT2A Q03164 1/20 0.53
MAOB P27338 2/20 0.51
BCHE P06276 1/20 0.51
EPHX2 P34913 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13840614 0.84 KMT2A (0.53) LMNACYP1A2PTGS1SLC6A2CYP2C19
SCHEMBL10477884 0.84 KMT2A (0.53) LMNACYP1A2PTGS1SLC6A2CYP2C19
SCHEMBL3923237 0.84 KMT2A (0.53) LMNACYP1A2PTGS1SLC6A2CYP2C19
SCHEMBL7145799 0.84 KMT2A (0.53) LMNACYP1A2PTGS1SLC6A2CYP2C19
SCHEMBL19734599 0.84 LMNA (0.56) LMNACYP1A2PTGS1SLC6A2CYP2C19
SCHEMBL26563983 0.83 KMT2A (0.59) LMNACYP1A2PTGS1SLC6A2CYP2C19
SCHEMBL10477980 0.81 KMT2A (0.50) LMNACYP1A2PTGS1SLC6A2CYP2C19
SCHEMBL10772009 0.81 SLC2A1 (0.63) PTGS1SLC6A2SLC6A3HIF1AMEN1
SCHEMBL7144139 0.81 ADRB2 (0.70) PTGS1SLC6A2SLC6A3HIF1A
SCHEMBL7144137 0.81 ADRB2 (0.70) PTGS1SLC6A2SLC6A3HIF1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8101804-B2 Process for the synthesis of (E)-stilbene derivatives which makes it possible to obtain resveratrol and piceatannol CLARIANT SPECIALTY FINE CHEMICALS (FRANCE) (FR) 2012-01-24 US claimed
US-20100004483-A1 Novel Process For The Synthesis Of (E)-Stilbene Derivatives Which Makes It Possible To Obtain Resveratrol And Piceatannol CLARIANT SPECIALTY FINE CHEMICALS (FRANCE) (FR) 2010-01-07 US claimed
EP-2049459-A1 NOVEL PROCESS FOR THE SYNTHESIS OF (E)-STILBENE DERIVATIVES WHICH MAKES IT POSSIBLE TO OBTAIN RESVERATROL AND PICEATANNOL Clariant Specialty Fine Chemicals (France) (FR) 2009-04-22 EP claimed
WO-2008012321-A1 NOVEL PROCESS FOR THE SYNTHESIS OF (E)-STILBENE DERIVATIVES WHICH MAKES IT POSSIBLE TO OBTAIN RESVERATROL AND PICEATANNOL CLARIANT SPECIALTY FINE CHEMICALS (FRANCE) (FR) 2008-01-31 WO claimed
EP-2049459-B1 NOVEL PROCESS FOR THE SYNTHESIS OF (E)-STILBENE DERIVATIVES WHICH MAKES IT POSSIBLE TO OBTAIN RESVERATROL AND PICEATANNOL CLARIANT SPECIALTY FINE CHEM F (FR) 2013-10-02 EP disclosed
US-8101804-B2 Process for the synthesis of (E)-stilbene derivatives which makes it possible to obtain resveratrol and piceatannol CLARIANT SPECIALTY FINE CHEMICALS (FRANCE) (FR) 2012-01-24 US disclosed
EP-2202215-A2 Novel process for the synthesis of (E)-Stilbene derivatives which makes it possible to obtain resveratrol and piceatannol Clariant Specialty Fine Chemicals (France) (FR) 2010-06-30 EP disclosed
US-20100004483-A1 Novel Process For The Synthesis Of (E)-Stilbene Derivatives Which Makes It Possible To Obtain Resveratrol And Piceatannol CLARIANT SPECIALTY FINE CHEMICALS (FRANCE) (FR) 2010-01-07 US disclosed
EP-2049459-A1 NOVEL PROCESS FOR THE SYNTHESIS OF (E)-STILBENE DERIVATIVES WHICH MAKES IT POSSIBLE TO OBTAIN RESVERATROL AND PICEATANNOL Clariant Specialty Fine Chemicals (France) (FR) 2009-04-22 EP disclosed
WO-2008012321-A1 NOVEL PROCESS FOR THE SYNTHESIS OF (E)-STILBENE DERIVATIVES WHICH MAKES IT POSSIBLE TO OBTAIN RESVERATROL AND PICEATANNOL CLARIANT SPECIALTY FINE CHEMICALS (FRANCE) (FR) 2008-01-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100004483-A1 Novel Process For The Synthesis Of (E)-Stilbene Derivatives Which Makes It Possible To Obtain Resveratrol And Piceatannol SQLE, SUCLA2, SORD LMNA 2065/4885CYP1A2 582/4885PTGS1 543/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.